Danaher Corporation (US) and Beam Therapeutics (US) are Leading Players in the Base Editing Market
The base editing market is projected to reach USD 549 million by 2028 from an estimated USD 270 million in 2023, at a CAGR of 15.2% during the forecast period. The base editing market is driven by its precision in genetic modification for therapeutic use, facilitated by ongoing R&D, collaborations between sectors, and substantial investments. Its potential spans disease-specific treatments, regulatory compliance, and diverse applications in agriculture, industry, and oncology, shaping its growth trajectory.
Players in the base editing market have adopted various strategies to advance the technology and expand its applications. These companies are engaged in research and development, collaborations, and partnerships to advance base editing technology and bring it to the market. For example, in January 2022, pharmaceutical companies such as Pfizer and Beam Therapeutics collaborated to develop in vivo base editing programs for rare diseases.
To know about the assumptions considered for the study download the pdf brochure
Danaher Corporation (US)
Danaher is a leading player in the base editing market. Danaher operates in the base editing market through its subsidiary Integrated DNA Technologies. Integrated DNA Technologies, Inc. (IDT) is dedicated to advancing the field of science. The company specializes in providing oligonucleotides, short strands of DNA and RNA, to research and development organizations. Owing to its strong sales and distribution network, the company has a significant global footprint. It focuses on investing more in research & development of new molecular technologies. For instance, the company has a strong emphasis on research, as the company invested around USD 1.5 Billion in research & development in 2022.
Beam Therapeutics (US)
Beam Therapeutics is a key player in the base editing market. The company has a growing portfolio of proprietary gene editing technologies, including base editing, prime editing, nuclease editing, and RNA editing, which can be customized for specific diseases and create new therapeutic programs. The company has also engaged in research collaborations with pharmaceutical companies such as Pfizer to develop in vivo base editing programs for rare diseases. Furthermore, the company has announced portfolio priorities and plans to streamline its business operations to support potential near-term value drivers and long-term growth, including cost reduction initiatives that align with the company's near-term goals.
Merck KGaA (Germany)
Merck is a leading science and technology company with a strong global presence in more than 120 countries. The company has a portfolio of more than 300,000 life science products that support a broad customer base. Merck majorly focuses on expansions in key geographies to increase its customer base. For instance, in June 2022, the company planned to open a 220,000-square-foot Discovery Center in London for discovery, research, and clinical purposes. In the last three years, the firm opened life science centers in China, India, South Korea, and Singapore to facilitate the supply of its products in the region. For instance, in September 2022, Merck inaugurated its Healthcare Research and Development Center in Bengaluru.
Related Reports:
Base Editing Market by Product (Platform, Reagents & Kits, Plasmids), Service (gRNA Design, Cell Line Engineering), Type, Targeted base (Cytosine, Adenine), Application (Drug Discovery, Agriculture, Veterinary), and Region - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
